Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)

被引：0
|
作者：
Miller, R. E. [1 ]
Bajrami, I. [1 ]
Brough, R. [1 ]
Konde, A. [1 ]
Campbell, J. [1 ]
Rafiq, R. [1 ]
Ashworth, A. [1 ]
Lord, C. J. [1 ]
机构：
[1] Inst Canc Res, London SW3 6JB, England
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70444-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
318
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [21] Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations
    Bitler, Benjamin G.
    Aird, Katherine M.
    Zhang, Rugang
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (01):
  • [22] Evidence Supporting Endometriosis as a Precursor of Ovarian Clear Cell and Endometrioid Carcinoma Based on Expression of ARID1A
    Ayhan, A.
    Mao, T-L
    Wu, C-H
    Ogawa, H.
    Futagami, M.
    Mizukami, H.
    Yokoyama, Y.
    Kurman, R. J.
    Shih, I-M
    MODERN PATHOLOGY, 2012, 25 : 259A - 259A
  • [23] Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma
    Li, Shang
    Meersma, Gert Jan
    Kupryjanczyk, Jolanta
    de Jong, Steven
    Wisman, G. Bea A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [24] Molecular characterization of a panel of ovarian clear cell carcinoma (OCCC) cell lines
    Huang, R.
    Ye, J.
    Kuay, K. T.
    Tan, T. Z.
    Heong, V.
    Tan, D. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma
    Kuroda, Takafumi
    Ogiwara, Hideaki
    Sasaki, Mariko
    Takahashi, Kazuaki
    Yoshida, Hiroshi
    Kiyokawa, Takako
    Sudo, Kazuki
    Tamura, Kenji
    Kato, Tomoyasu
    Okamoto, Aikou
    Kohno, Takashi
    GYNECOLOGIC ONCOLOGY, 2019, 155 (03) : 489 - 498
  • [26] SENSITIVITY TO CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ACCORDING TO ARID1A DEFICIENCY OF OVARIAN CLEAR CELL CARCINOMA AND ENDOMETRIOID CARCINOMA CELLS
    Kuroda, T.
    Ogiwara, H.
    Takahashi, K.
    Sasaki, M.
    Yoshida, H.
    Kato, T.
    Okamoto, A.
    Kohno, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 180 - 180
  • [27] Exploring the therapeutic effectiveness of EO3001 in the treatment of clear cell ovarian cancers with ARID1A mutations
    Ding, Yuchen
    Li, Lucy Yuqin
    Zhang, Joyce Yuhan
    Kabeer, Farhia
    Lam, TszYin
    Kalantari, Forouh
    Bacha, Jeffrey
    Brown, Dennis
    Kanekal, Sarath
    Sankar, Neil
    Lizardo, Michael
    El-Naggar, Amal
    Huntsman, David
    CANCER RESEARCH, 2024, 84 (05)
  • [28] Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers
    Lowery, W.
    Schildkraut, J.
    Akushevich, L.
    Bentley, R.
    Huntsman, D.
    Marks, J.
    Berchuck, A.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S21 - S21
  • [29] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component (vol 67, pg 866, 2014)
    Nishikimi, K.
    Kiyokawa, T.
    Tate, S.
    Iwamoto, M.
    Shozu, M.
    HISTOPATHOLOGY, 2016, 68 (04) : 621 - 621
  • [30] Synthetic lethal interaction between ARID1A mutation and BET bromodomain inhibition in ovarian clear cell carcinoma
    Berns, Katrien
    Caumanns, Joseph J.
    Hijmans, E. Marielle
    Gennissen, Annemiek
    Evers, Bastiaan
    Wisman, Bea A.
    Meersema, Gert Jan
    Lieftink, Cor
    Beijersbergen, Roderick L.
    Itamochi, Hiroaki
    van der Zee, Ate G.
    de Jong, Steven
    Bernards, Rene
    CANCER RESEARCH, 2017, 77
12345